Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Other Accumulated Expenses data on record, last reported at $50000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 96.27% year-over-year to $50000.0; the TTM value through Sep 2025 reached $50000.0, down 96.27%, while the annual FY2024 figure was $3.2 million, 103.82% up from the prior year.
  • Other Accumulated Expenses reached $50000.0 in Q3 2025 per CTNM's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.2 million in Q4 2024 and bottomed at $50000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 3 years is $1.2 million, with a median of $1.4 million recorded in 2023.
  • The widest YoY moves for Other Accumulated Expenses: up 3142.31% in 2025, down 96.71% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $1.5 million in 2023, then surged by 103.82% to $3.2 million in 2024, then crashed by 98.41% to $50000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $50000.0 in Q3 2025, $1.7 million in Q2 2025, and $62000.0 in Q1 2025.